Antipsychotics and parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 49, Issue 7, 2002, Pages 157-161

  van de Vijver, D A M C ^a   Roos, R A C ^b   Jansen, P A F ^c   Porsius, A J ^a   De Boer, A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotics; Clozapine; Haloperidol; Levodopa; Pharmacoepidemiology

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; HALOPERIDOL; LEVODOPA; AMANTADINE; BIPERIDEN; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXETIMIDE; LISURIDE; NEUROLEPTIC AGENT; OLANZAPINE; ORPHENADRINE; PERGOLIDE; PIPAMPERONE; PRAMIPEXOLE; PROCHLORPERAZINE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL; ZUCLOPENTHIXOL;

AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INFORMATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; AGE; DISEASE ASSOCIATION; DRUG CHOICE; DRUG USE; GENDER; PHARMACY;

AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0036244907     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Psychotic complications of long-term levodopa treatment of Parkinson's disease
2. Visual hallucinations associated with Parkinson disease
3. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
4. Risk factors for nursing home placement in advanced Parkinson's disease
5. Pharmacology of hallucinations induced by long-term drug therapy
6. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
7. Neuropsychiatric complications of Parkinson's disease
8. Drug treatment of Parkinson's disease
9. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
10. Clozapine in drug-induced psychosis in Parkinson's disease
11. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
12. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities
13. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study
14. Differences in drug prescribing patterns in elderly parkinsonian patients identified at hospital admission
15. Pharmacomorbidity linkage: A feasibility study comparing morbidity in two pharmacy based exposure cohorts
16. Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease
17. Prevalence of Parkinson's disease in the elderly: The Rotterdam study
18. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study
19. Applied survival analysis
20. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine
21. Clozapine is beneficial for psychosis in Parkinson's disease
22. Clozapine: A 2-year open trial in Parkinson's disease patients with psychosis
23. Clozapine therapeutic plunge in patient with Parkinson's disease
24. An algorithm for the management of Parkinson's disease
25. Parkinson's disease: Drug-induced psychiatric states
26. Clozapine in the treatment of psychosis in Parkinson's disease
27. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
28. Risperidone in Parkinson's disease
29. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note
30. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients